License Agreement Sample Contracts

Share Cite Term
Link

Embed (HTML)
Envoy Group Corp. – Exclusive Softward License Agreement Amendment No. One (December 13th, 2017)

THIS AMENDMENT NO. ONE TO THAT CERTAIN EXCLUSIVE SOFTWARE LICENSE AGREEMENT (the "First Amendment") is made and dated this 12th day of December, 2017 by and between Black Cactus Holdings, LLC, a Delaware limited liability company ("Licensor") and Black Cactus Global, Inc. formerly known as Envoy Group Corp., a Florida corporation ("Licensee").

OUTFRONT Media Inc. – Advertising License Agreement (December 13th, 2017)

THIS ADVERTISING LICENSE AGREEMENT (the "License Agreement") is by and between the METROPOLITAN TRANSPORTATION AUTHORITY and Outfront Media Group LLC, a limited liability company organized and existing under the laws of Delaware (the "Concessionaire").

License Agreement (Cbs Sports Radio Brand) (November 17th, 2017)

This TRADEMARK LICENSE AGREEMENT (CBS SPORTS RADIO BRAND) (this Agreement), dated as of November 16, 2017 (the Effective Date), is by and between CBS Broadcasting Inc., a New York corporation (the Licensor), and CSTV Networks, Inc. d/b/a CBS Sports Network (CBSSN), one the one hand, and CBS Sports Radio Network Inc., a Delaware corporation (CBSRN), and CBS Radio Inc., a Delaware corporation (Radio and collectively with CBSRN, and Radios wholly-owned direct and indirect Subsidiaries identified in Schedule 2, the Licensees), on the other hand. Unless otherwise defined in this Agreement, all capitalized terms used in this Agreement shall have the meanings set forth in the Master Separation Agreement, dated as of February 2, 2017, by and between CBS Corporation, a Delaware corporation (CBS) and Radio (as amended, modified or supplemented from time to time in accordance with its terms, the Separation Agreement).

Hudson Ltd. – HUDSON Trademark License Agreement (November 14th, 2017)

I. PARTIES 1 II. RECITALS 2 III. DEFINITIONS AND INTERPRETATION 3 A. DEFINITIONS 3 B. INTERPRETATION GUIDELINES 4 IV. COVENANTS 5 Article 1 Object 5 Article 2 Territory 5 Article 3 IP Rights 5 Article 4 Validity - Effective Date 5 Article 5 Sub-Licence 5 Article 6 Remuneration 5 Article 7 Licensee's Rights And Obligations 6 7.1 Exercise of Trademark 6 7.2 Use of Intellectual Property 6 Article 8 DIAG's Rights And Obligations 6 8.1 Provision of Materials 6 8.2 Exclusivity 6 8.3 Trademark Maintenance 6 Article 9 Ownership Of Intellectual Property 6 Article 10 Registration Of HGI As Registered User 6 Article 11 Other Marketing Intangibles

Regenerx Biopharmaceuticals – Amendment NO. 2 to RGN-137 LICENSE Agreement (November 14th, 2017)

This Amendment No. 2 to License Agreement (this "Amendment"), effective as of August 28, 2017 (the "Effective Date"), amends that certain License Agreement (the "Agreement" or the "License Agreement"), dated effective March 7, 2014, by and between RegeneRx Biopharmaceuticals, Inc., (hereinafter "Licensor"), and GtreeBNT Co., Ltd. (formerly Digital Aria Co., Ltd.) (hereinafter "Licensee"), each a "Party" and, collectively, the "Parties."

Palatin Technologies, Inc. – LICENSE AGREEMENT by and Between SHANGHAI FOSUN PHARMACEUTICAL INDUSTRIAL DEVELOPMENT CO. LTD. And PALATIN TECHNOLOGIES, INC. September 6, 2017 (November 13th, 2017)

This License Agreement (the "Agreement") is entered into as of September 6, 2017 (the "Effective Date"), by and between Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., a limited liability company organized and existing under the laws of the People's Republic of China and having a registered principal place of business at No. 1289 Yishan Road (Building A, Fosun Technology Park), Shanghai City, 200233, the People's Republic of China ("Fosun") and Palatin Technologies, Inc., a corporation organized and existing under the laws of Delaware and having a principal place of business at 4-B Cedar Brook Drive, Cedar Brook Corporate Center, Cranbury, NJ 08512 ("Palatin"). Fosun and Palatin may each be referred to herein individually as a "Party" and collectively as the "Parties."

Cellectis S.A. – License Agreement (November 13th, 2017)

This LICENSE AGREEMENT (this Agreement), dated as of July 25, 2017 (the Effective Date), is entered into by and between Cellectis S.A., a corporation existing and registered under the laws of France, located at 8 rue de la Croix Jarry, 75013 Paris, France (Cellectis), and Calyxt, Inc., a corporation existing and registered under the laws of Delaware, located at 600 County Road D West, Suite 8, New Brighton, MN 55112, USA (Calyxt) (each a Party and collectively, the Parties).

Tabula Rasa HealthCare, Inc. – License Agreement and Asset Transfer Between the Arizona Board of Regents on Behalf of the University of Arizona and Sinfonia Healthcare Corp. Arizona File Ua09-108 (November 9th, 2017)

This License Agreement and Asset Transfer (the "AGREEMENT") is made effective as of the EFFECTIVE DATE and is between The Arizona Board of Regents on behalf of The University of Arizona, an Arizona body corporate with its principal campus in Tucson, Arizona 85721 ("ARIZONA"), and Sinfonia Healthcare Corporation, a Delaware corporation with its principal place of business at One East Toole, Tucson, AZ 85701 ("LICENSEE").

Tabula Rasa HealthCare, Inc. – First Amendment to License Agreement and Asset Transfer Between the Arizona Board of Regents on Behalf of the University of Arizona and Sinfonia Healthcare Corp. Arizona File UA09-108 (November 9th, 2017)

This First Amendment to License Agreement and Asset Transfer (the "First Amendment") is made effective on the date of the last authorized signature below ("Amendment Effective Date") and is between The Arizona Board of Regents on behalf of The University of Arizona, an Arizona body corporate with its principal campus in Tucson, Arizona 85721 ("ARIZONA"), and Sinfonia Healthcare Corporation, a Delaware corporation with its principal place of business at One East Toole, Tucson, AZ 85701 ("LICENSEE"). Capitalized terms used but not defined in this First Amendment will have the meanings assigned to such terms in the Agreement.

ImmunoGen, Inc. – Amendment No. 3 to Collaborative Development and License Agreement (November 9th, 2017)

This Amendment No. 3 (this "Amendment No. 3") to the Collaborative Development and License Agreement entered into as of July 7, 2006 (the "Agreement Effective Date"), as amended as of August 23, 2006 and December 10, 2014 (the "Agreement") by and between ImmunoGen, a Massachusetts corporation with its principal place of business at 830 Winter Street, Waltham, Massachusetts 02451, USA ("ImmunoGen") and Biotest AG, a corporation organized under the laws of Germany having an address of Landsteinerstrasse 5, D-63303 Dreieich, Germany ("Biotest") is dated as of October 26, 2017.

BioDelivery Sciences International, Inc. – License Agreement (November 9th, 2017)

This License Agreement (Agreement) is made as of July 12, 2017 (the Effective Date) by and between BioDelivery Sciences International, Inc., a Delaware corporation with its principal offices at 4131 Parklake Avenue, Suite 225, Raleigh, North Carolina 27612 (Parent), its wholly-owned subsidiary Arius Pharmaceuticals, Inc., a Delaware corporation with an office at the same address (Arius, and together with Parent, BDSI), and Purdue Pharma, an Ontario limited partnership with its principal office at 575 Granite Court, Pickering, ON Canada L1W 3W8 (Purdue). BDSI and Purdue are sometimes referred to collectively herein as the Parties or singly as a Party.

Virnetx Holding Corp – AMENDED AND RESTATED GABRIEL LICENSE AGREEMENT BY AND BETWEEN VIRNETX HOLDING CORPORATION AND PUBLIC INTELLIGENCE TECHNOLOGY ASSOCIATES October 18, 2017 (November 9th, 2017)

This AMENDED AND RESTATED GABRIEL LICENSE AGREEMENT (this "Agreement") dated as of October 18, 2017 ("Effective Date"), is by and between VirnetX Holding Corporation, a Delaware corporation with an address at 308 Dorla Ct., Zephyr Cove, NV 89448, U.S.A. (the "Company"), and Public Intelligence Technology Associates, kk (Japanese Corporation) with an address at 27F Yomiuri Tokyo Head Office Building, 1-7-1 Otemachi, Chiyoda-ku, Tokyo, 100-8055, Japan ("Representative").

License Agreement (November 9th, 2017)

LICENSE AGREEMENT (this "Agreement") dated August 17, 2017 (the "Effective Date") by and between BioTime, Inc,, a corporation incorporated under the laws of the State of California, United States of America ("BioTime"), and AgeX Therapeutics, Inc., a corporation incorporated under the laws of the State of Delaware, United States of America ("AgeX") (each, a "Party" and, collectively, the "Parties").

License Agreement (November 8th, 2017)

This License Agreement (this Agreement) is dated as of September 5, 2017 (the Effective Date) by and between Presage Biosciences, Inc., a corporation organized under the laws of Delaware and having a place of business at 530 Fairview Avenue North, Suite 1000, Seattle, WA 98109 (Presage), and MEI Pharma, Inc., a corporation organized under the laws of the state of Delaware and having a place of business at 3611 Valley Centre Drive, Suite 500, San Diego, CA 92130 (MEI). Presage and MEI may be referred to herein as a Party or, collectively, as the Parties.

Snap Inc – Amendment to Google Cloud Platform License Agreement (November 8th, 2017)

This Amendment ("Amendment") is entered into by Snap Inc. ("Snap US"), Snap Group Limited ("Snap UK") and Google Inc. ("Google"). This Amendment amends the Google Cloud Platform License Agreement effective January 30, 2017, by and between Snap US and Google, (the "Agreement"). This Amendment is effective as of the date last signed by the parties below (the "Amendment Effective Date"). Capitalized terms not defined in this Amendment will have the meaning ascribed to them under the Agreement.

License Agreement (November 8th, 2017)

This LICENSE AGREEMENT (this "Agreement") is effective as of the HSR Clearance Date (the "Effective Date") and is entered into by and between:

Amendment No. 1 to License Agreement (November 7th, 2017)

This Amendment No 1 ("Amendment") to the License Agreement (as defined below) dated as of August 3, 2017 (the "Amendment Date"), is entered into by and between "Shang Hai Si Dan Sai Sheng Wu iJi Zhu You Xian Gong Si " (Innovative Cellular Therapeutics CO., LTD.), a corporation organized and existing under the laws of China ("ICT"), and Vericel Corporation, a corporation organized and existing under the laws of the State of Michigan ("Vericel"). Terms used, but not defined, herein shall have the meaning ascribed to them in the License Agreement.

Max-1 Acquisition Corp – License Agreement (November 7th, 2017)

This Agreement is made with effect from May 27th, 2014 (the "Effective Date"), by and between Northwestern University, an Illinois not-for-profit corporation with a principal place of business at 633 Clark Street, Evanston, Illinois 60208 ("Northwestern") and Exicure Inc., a Delaware corporation, with a principal place of business at 8045 Lamon Avenue, Suite 410, Skokie, IL 60077 ("Licensee").

Amendment No. 2 to License Agreement (November 7th, 2017)

This Amendment No 2 ("Amendment") to the License Agreement (as defined below) dated as of September 5, 2017 (the "Amendment Date"), is entered into by and between "Shang Hai Si Dan Sai Sheng Wu iJi Zhu You Xian Gong Si " (Innovative Cellular Therapeutics CO., LTD.), a corporation organized and existing under the laws of China ("ICT"), and Vericel Corporation, a corporation organized and existing under the laws of the State of Michigan ("Vericel"). Terms used, but not defined, herein shall have the meaning ascribed to them in the License Agreement.

Max-1 Acquisition Corp – License Agreement (November 7th, 2017)

This Agreement is made with effect from June 17th, 2016 (the "Effective Date"), by and between Northwestern University, an Illinois not-for-profit corporation with a principal place of business at 633 Clark Street, Evanston, Illinois 60208 ("Northwestern") and Exicure Inc., a Delaware corporation, with a principal place of business at 8045 Lamon Avenue, Suite 410, Skokie, IL 60077 ("Licensee").

Nanotherapeutics License Agreement (November 6th, 2017)

This NANOTHERAPEUTICS LICENSE AGREEMENT (this "Agreement") is entered into as of March 23, 2016 (the "Effective Date") by and between XOMA (US) LLC, a Delaware limited liability company ("Licensor), and Nanotherapeutics, Inc., a Delaware Corporation ("Licensee"). Each of Licensor and Licensee is sometimes referred to individually herein as a "Party" and collectively as the "Parties."

Dermira, Inc. – License Agreement (November 6th, 2017)

[*****] Certain portions denoted with an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

LICENSE AGREEMENT by and Between XOMA (US) LLC and NOVARTIS PHARMA AG (November 6th, 2017)

This LICENSE AGREEMENT (the "Agreement") is entered into as of the 24th day of August, 2017 (the "Effective Date") by and between XOMA (US) LLC, a limited liability company organized under the laws of Delaware having offices at 2910 Seventh St., Berkeley, CA, USA, 94710 ("XOMA"), and Novartis Pharma AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland and registered in the Commercial Register of the Canton of Basel-Stadt, Switzerland, under number CHE-106.052.527 whose registered office is at Lichtstrasse 35, 4056 Basel, Switzerland ("Novartis"). XOMA and Novartis are each referred to herein by name or as a "Party" or, collectively, as the "Parties."

IL-1 TARGET LICENSE AGREEMENT by and Between XOMA (US) LLC and NOVARTIS PHARMA AG (November 6th, 2017)

This IL-1 TARGET LICENSE AGREEMENT (the "Agreement") is entered into as of the 24th day of August, 2017 (the "Effective Date") by and between XOMA (US) LLC, a limited liability company organized under the laws of Delaware having offices at 2910 Seventh St., Berkeley, CA, USA, 94710 ("XOMA"), and Novartis Pharma AG, company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland and registered in the Commercial Register of the Canton of Basel-Stadt, Switzerland, under number CHE-106.052.527 whose registered office is at Lichtstrasse 35, CH 4056 Basel, Switzerland ("Novartis"). XOMA and Novartis are each referred to herein by name or as a "Party" or, collectively, as the "Parties."

GraniteShares Platinum Trust – License Agreement (November 3rd, 2017)

THIS LICENSE AGREEMENT (this "Agreement") is entered into effective as of the 3rd day of July, 2017 (the "Effective Date"), by and between The Bank of New York Mellon, a New York banking corporation ("Licensor"), and GraniteShares LLC, a Delaware limited liability company, as sponsor to Licensed Products as defined below ("Licensee").

License Agreement (November 3rd, 2017)
Amendment No. 7 to License Agreement Between Insmed Incorporated and Pari Pharma Gmbh (November 2nd, 2017)

This seventh amendment ("Amendment No. 7") effective 21 July 2017 ("Amendment No. 7 Effective Date") to the License Agreement dated and effective the 25th of April 2008 between PARI Pharma GmbH, a German corporation with a principal place of business at Moosstrasse 3, D-82319 Starnberg, Germany ("PARI") and Transave, Inc., a Delaware corporation, as amended by Amendment No. 1 the 24th day of June 2009, Assignment and Amendment No. 2 the 22nd day of December 2010, Amendment No. 3 the 6th day of March 2012, Amendment No. 4 the 21st day of May 2012, Amendment No. 5 the 5th day of October 2015 and Amendment No. 6 the 9th day of October 2015 (collectively, the "Agreement"), is entered into between PARI and Insmed Incorporated (successor in interest to Transave, Inc.), with registered offices at 10 Finderne Avenue, Building 10, Bridgewater, NJ 08807-3365 ("Insmed"). PARI and Insmed shall be referred to collectively as the "Parties".

Sa Recovery Corp – License Agreement (October 31st, 2017)

This License Agreement (this "Agreement"), effective as of October [ ], 2017 (the "Effective Date"), is by and among Recruiter.com, Inc., a Delaware corporation ("Recruiter"), VocaWorks, Inc. a New Jersey corporation ("Sub") and Truli Media Group, Inc., a Delaware corporation ("Parent"). Recruiter, Sub and Parent may be referred to herein collectively as the "Parties" or individually as a "Party."

License Agreement (October 30th, 2017)

License Agreement made as of the 20th day of March 2017, by and between Madison Avenue Suites LLC and Sellas Life Sciences Group Inc

Allena Pharmaceuticals, Inc. – License Agreement (October 23rd, 2017)

This License Agreement (this Agreement) is entered into as of the 22 day of March 2012 (the Effective Date) by and between Althea Technologies, Inc., a Delaware corporation with its principal place of business at 11040 Roselle Street, San Diego, CA 92121 (Althea), and Allena Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at One Newton Executive Park, Suite 202, Newton, MA 02462 (Allena).

American Education Center, Inc. – License Agreement (October 23rd, 2017)

This License Agreement, executed as of 20th day of October, 2017 (the "Effective Date") between American Education Center Inc., a Nevada corporation (hereinafter named "Licensee") and Max P. Chen (hereinafter named "Licensor") (collectively, the "Parties"), sets forth the following:

scPharmaceuticals Inc. – License Agreement (October 23rd, 2017)

This LICENSE AGREEMENT (this Agreement) is made and entered into as of June 29, 2015 (the Effective Date), by and among scPharmaceuticals Inc., having an address at 131 Hartwell Avenue, Suite 215, Lexington, MA 02421 (scPharma) and Sensile Medical AG, having an address at Fabrikstrasse 10, CH-4614 Hagendorf, Switzerland (Sensile Med) and Sensile Holding AG (Sensile Holding) and Sensile Patent AG (Sensile Patent), both having an address at Zuger Strasse 76b, CH-6340, Baar, Switzerland (Sensile Med, Sensile Holding and Sensile Patent together in any combination, Sensile) (each of scPharma, Sensile Med, Sensile Holding and Sensile Patent, a Party and, collectively, the Parties),

Syndax Pharmaceuticals Inc – Risks Related to Intellectual Property if We Breach the Allergan License Agreement Related to the Menin Assets or if the Allergan License Agreement Is Otherwise Terminated, We Could Lose the Ability to Continue the Development and Commercialization of the Menin Assets. (October 17th, 2017)

Our commercial success depends upon our ability to develop, manufacture, market and sell one or more of the Menin Assets. Subject to the achievement of certain milestone events, we may be required to pay Allergan up to $99 million in one-time development and regulatory milestone payments over the term of the Allergan license agreement. In the event that we or any of our affiliates or sublicensees commercializes any of the Menin Assets, we will also be obligated to pay Allergan low single to low double-digit royalties on sales, subject to reduction in certain circumstances, as well as up to an aggregate of $70 million in potential one-time sales-based milestone payments based on achievement of certain annual sales thresholds. Under certain circumstances, we may be required to share a percentage of non-royalty income from sublicensees, subject to certain deductions, with Allergan.

Vascular Biogenics Ltd. – Crucell Holland B.V. - Vascular Bio Genics Ltd. Commercial Gene Therapy License Agreement (October 11th, 2017)

This Commercial Gene Therapy License Agreement ("Agreement") is made and entered into on April 15, 2011 ("EFFECTIVE DATE") by and between:

Spero Therapeutics, Inc. – CONFIDENTIAL TREATMENT REQUESTED LICENSE AGREEMENT BY AND BETWEEN MEIJI SEIKA PHARMA CO., LTD. AND SPERO OPCO, INC. Portions of This Exhibit, Indicated by the Mark [***], Were Omitted and Have Been Filed Separately With the Securities and Exchange Commission Pursuant to the Registrants Application Requesting Confidential Treatment Pursuant to Rule 406 of the Securities Act of 1933, as Amended. (October 6th, 2017)

This License Agreement (this Agreement) is made and effective as of the 14th day of June, 2017 (the Effective Date) by and between Meiji Seika Pharma Co., Ltd., a Japanese corporation with offices at 2-4-16, Kyobashi, Chuo-ku, Tokyo, 104-8002 Japan (Meiji) and Spero OpCo, Inc., a Delaware corporation with offices at 675 Massachusetts Avenue, 14th Floor, Cambridge, MA 20139, USA (Spero).